Q1 2025

Filed May 12, 2025 · 10-Q · 42 days after period end · 0000950170-25-069314

Q1 2025 · 10-Q

Revenue—

Net Income

-$18.18M

N/M vs Q1 2024

EPS Diluted

-$0.25

N/M vs Q1 2024

Operating Income-$21,832,000N/M

Operating Cash Flow-$21,582,000N/M

Same quarter

Metric	Q1 2025	Q1 2024	Q1 2023	Q1 2022
Revenue	—	—	$2.06M	$2.91M
Net Income	-$18.18M	-$12.28M	-$371.00K	-$1.35M
EPS Diluted	-$0.25	-$0.25	$0.00	—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR